ES2171392T3 - Poliligandos de proteina unidos a un nucleo de proteina estable. - Google Patents

Poliligandos de proteina unidos a un nucleo de proteina estable.

Info

Publication number
ES2171392T3
ES2171392T3 ES91918175T ES91918175T ES2171392T3 ES 2171392 T3 ES2171392 T3 ES 2171392T3 ES 91918175 T ES91918175 T ES 91918175T ES 91918175 T ES91918175 T ES 91918175T ES 2171392 T3 ES2171392 T3 ES 2171392T3
Authority
ES
Spain
Prior art keywords
protein
stable
polygands
united
nucleus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918175T
Other languages
English (en)
Inventor
Jean-Paul Soulillou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Regional de Nantes
Original Assignee
Centre Hospitalier Regional de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional de Nantes filed Critical Centre Hospitalier Regional de Nantes
Application granted granted Critical
Publication of ES2171392T3 publication Critical patent/ES2171392T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LOS POLILIGANDOS ESTABLES SE OBTIENEN A BASE DE PREPARAR PROTEINAS FUSIONADAS, DONDE LAS PROTEINAS FUSIONADAS CONTIENEN UN LIGANDO EN UN TERMINAL Y UNA PROTEINA DE SUBUNIDAD O DE UNIDAD MULTIMERICA EN EL OTRO TERMINAL, DONDE LA PROTEINA FUSIONADA ES CAPAZ DE ENLAZARSE PARA PROPORCIONAR UN POLILIGANDO. LOS POLILIGANDOS SE PUEDEN UTILIZAR EN LA MODULACION DE PROCESOS FISIOLOGICOS A BASE DE INHIBIR LA TRANSDUCCION DE SEÑAL INDUCIDA POR EL LIGANDO MEDIANTE RECEPTORES DE PROTEINAS DE MEMBRANA SUPERFICIAL Y/O EN EL CASO DE UTILIZAR UNA CADENA (MU), A BASE DE MATAR CON EFECTIVOS O CUALQUIER OTRA FUNCION EFECTORA. LA MOLECULA PUEDE ESTAR COMPUESTA UNICAMENTE DE COMPONENTES HUMANOS PARA EVITAR UNA RESPUESTA INMUNE POR PARTE DEL RECEPTOR.
ES91918175T 1990-08-29 1991-08-22 Poliligandos de proteina unidos a un nucleo de proteina estable. Expired - Lifetime ES2171392T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57539490A 1990-08-29 1990-08-29
US64687591A 1991-01-28 1991-01-28

Publications (1)

Publication Number Publication Date
ES2171392T3 true ES2171392T3 (es) 2002-09-16

Family

ID=27076683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918175T Expired - Lifetime ES2171392T3 (es) 1990-08-29 1991-08-22 Poliligandos de proteina unidos a un nucleo de proteina estable.

Country Status (7)

Country Link
US (1) US5672486A (es)
EP (1) EP0547163B1 (es)
JP (1) JPH06502301A (es)
CA (1) CA2090105A1 (es)
DE (1) DE69132925T2 (es)
ES (1) ES2171392T3 (es)
WO (1) WO1992003569A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
CA2354846A1 (en) 1998-12-23 2000-06-29 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
CN102805868A (zh) 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
CA2482924A1 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
EP1504010B1 (en) * 2002-05-15 2009-03-25 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP5902367B2 (ja) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US8465724B2 (en) * 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
CN101784565B (zh) * 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
JP7616671B2 (ja) 2019-06-24 2025-01-17 ウニヴェルズィテート シュトゥットガルト 改善された安定性を有するｔｎｆｒ２アゴニスト
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20230171964A (ko) 2021-04-16 2023-12-21 노파르티스 아게 폴레이트 수용체-표적화된 방사선 요법제 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2178635T3 (es) * 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.

Also Published As

Publication number Publication date
CA2090105A1 (en) 1992-03-01
US5672486A (en) 1997-09-30
JPH06502301A (ja) 1994-03-17
EP0547163A1 (en) 1993-06-23
EP0547163B1 (en) 2002-02-06
WO1992003569A1 (en) 1992-03-05
DE69132925T2 (de) 2002-10-10
EP0547163A4 (en) 1993-09-01
DE69132925D1 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
ES2171392T3 (es) Poliligandos de proteina unidos a un nucleo de proteina estable.
ATE350475T1 (de) Rezeptor an der oberfläche von aktivierten t- zellen:act4
DE69006786D1 (de) Aromatische Polyimid-Trennungsmembran.
ATE157547T1 (de) Verbesserungen bei kontrastmitteln
DE68910872D1 (de) Hydrokolloide enthaltende Klebemischung.
DE3770755D1 (de) Polyimidmembrane zur gastrennung.
DK0538404T3 (da) Fibroblaste vækstfaktorreceptorer
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DK258789D0 (da) Peptider, der blokerer bindingen af hiv-1 til cd4 receptorproteinet
FR2595588B1 (fr) Secoueur
FI896242A7 (fi) HIV-ENV-proteiineihin liittyviä synteettisiä peptidejä
DE68906566D1 (de) Dimerisierung von niedrigen alpha-olefinen.
DK12189A (da) Flydende membran apparat
DE68927623D1 (de) Folienschalter
NO873216L (no) Rekombinante htlv-iii-proteiner og anvendelse derav.
NO885725D0 (no) Sammenleggbar hagelenestol.
IT8721130A0 (it) Dispositivo per misurare il modulo di elasticita' e metodi particolarmente adatti per provare materiali cedevoli.
NO894573L (no) Rekombinante interleukin-2 hybridproteiner.
DK196088D0 (da) Rekombinant htlv-iii protein og anvendelse deraf
NO873512L (no) Human lav-affinitets fcepsilon-reseptor, isolering, rekombinant fremstilling og rensing av denne.
DE68927207D1 (de) Schaltung zur Signaturkompression
FI894072A7 (fi) Rokotteena käytettävät polypeptidit
ATE300612T1 (de) Theta-untereinheit des menschlichen gaba-a rezeptors
DE68909033D1 (de) Tragbares faltbares boot.
IT8740171A0 (it) Scotitoio meccanico per bottiglie shaker

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 547163

Country of ref document: ES